Sabine Brookman-May, Senior Vice President of Therapeutic Area and Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“TAR200 INLEXZO approved based on results of Sunrise1 in BCG-unresponsive NMIBC (CIS ± pap lesions).
This outcome was possible by the courage of all patients participating. No longer Johnson and Johnson Innovation, but happy to have been part of this story.
Results from SUNRISE1:
- 82.4% centrally confirmed CR rate.
- 95.7% of CRs achieved at the first disease assessment, with no need for re-induction.
- Median duration of response was 25.8 months.
- 51% of CRs with DOR ≥ 12 months.”
More posts featuring Sabine D. Brookman-May.